Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
How to Unlock FR Avancer Assault Rifle in Warzone Season 5
Prime Day Deals so good, they're literally free
Apple Is Working on a Revamped iPad Pro
The Best DSLR and Mirrorless Cameras for 2023
Andrew Tate asks fans 'when will you change?' as he urges them to embrace self-transformation, Internet says 'become a machine'
The Google Pixel Buds Pro are on sale at Amazon for 20% off
How much are 'TikTok challenges' to blame for recent tragedies?
Fortnite: 24.40 patch notes update on ranked mode, server downtime, spider-verse and balance changes